Open AccessAndrogen receptor and soy isoflavones in prostate cancer (Review)
Author(s) -
Monika Kmeťová Sivoňová,
Peter Kaplán,
Zuzana Tatarková,
Lucia Lichardusová,
Róbert Dušenka,
Jana Jurečeková
Publication year - 2018
Publication title -
molecular and clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.442
H-Index - 7
eISSN - 2049-9469
pISSN - 2049-9450
DOI - 10.3892/mco.2018.1792
Subject(s) - soy isoflavones , prostate cancer , androgen receptor , isoflavones , cancer , molecular medicine , oncogene , cancer research , medicine , biology , cell cycle
Androgens and androgen receptor (AR) play a critical role not only in normal prostate development, but also in prostate cancer. For that reason, androgen deprivation therapy (ADT) is the primary treatment for prostate cancer. However, the majority of patients develop castration-resistant prostate cancer, which eventually leads to mortality. Novel therapeutic approaches, including dietary changes, have been explored. Soy isoflavones have become a focus of interest because of their positive health benefits on numerous diseases, particularly hormone-related cancers, including prostate and breast cancers. An important strategy for the prevention and/or treatment of prostate cancer might thus be the action of soy isoflavones on the AR signaling pathway. The current review article provides a detailed overview of the anticancer potential of soy isoflavones (genistein, daidzein and glycitein), as mediated by their effect on AR.